Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Price Up 3.9% – Should You Buy?

Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report) shot up 3.9% during trading on Friday. The stock traded as high as $37.61 and last traded at $37.08. Approximately 1,282,373 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 3,376,665 shares. The stock had previously closed at $35.68.

Mind Medicine (MindMed) Stock Performance

The stock has a 50 day moving average of $37.91 and a 200-day moving average of $29.32.

About Mind Medicine (MindMed)

(Get Free Report)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. The company focuses on psychedelic-inspired medicines intended to address conditions with significant unmet medical needs, including anxiety and mood disorders.

MindMed’s lead program, MM-120, is a proprietary formulation of lysergide, commonly known as LSD, being studied for generalized anxiety disorder and other neuropsychiatric conditions. The company is also developing MM-402, an ibogaine-derived therapy candidate intended for potential use in substance use and other brain-related disorders.

Founded in 2019, MindMed conducts research and clinical development activities through collaborations with academic institutions, medical researchers and other industry partners.

See Also

• Five stocks we like better than Mind Medicine (MindMed)
• Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
• DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
• FTC Puts A Wrinkle In the Cintas and UniFirst Merger
• Breaching the Valuation: The Real Reason Fortinet Dropped

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.